Skip to Content

Join the 'Doxycycline Hyclate' group to help and get support from people like you.

Doxycycline Hyclate News

Aqua Pharmaceuticals Announces FDA Approval of Acticlate (doxycycline hyclate USP) Tablets

Posted 28 Jul 2014 by Drugs.com

West Chester, Pa. — July 28, 2014 West Chester-based Aqua Pharmaceuticals, an Almirall company, today announces the U.S. Food and Drug Administration (FDA) approval of the NDA for Acticlate (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, thereby continuing Aqua’s leadership in medical dermatology and oral antibiotics for acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne. Acticlate will be entering the dermatology-focused, branded oral antibiotic market, which, according to IMS, is currently valued at $798 million. Acticlate 150 mg tablets have two functional scores, providing several dosing options to physicians and patients. The Acticlate film-coated, round 75 mg tablets and oval-shaped, dual-scored 150 mg tablets are designed to be small and easy to swallow. Utilization of the la ... Read more

Related support groups: Acne, Doxycycline, Bacterial Infection, Doxycycline Hyclate

Ask a Question